Saikosaponin‑D triggers cancer cell death by targeting the PIM1/c-Myc axis to reprogram oncogenic alternative splicing
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-06 19:37
摘要：
Saikosaponin-D (SSD), derived from Radix Bupleuri, has been identified as a potent anti-tumor agent targeting the PIM1/c-Myc axis. This study demonstrates SSD's ability to induce cancer cell death by reprogramming oncogenic alternative splicing in gastric and prostate cancers. The findings reveal that SSD significantly inhibits tumor growth in various cancer models, showcasing its potential as a therapeutic candidate. The research emphasizes the innovative mechanism of SSD, which disrupts the PIM1-Myc interaction, leading to decreased Myc phosphorylation and altered splicing factor expression, thereby providing a novel approach to cancer treatment.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0分
business_impact
0.5分
scientific_rigor
1.5分
timeliness_innovation
1.5分
investment_perspective
2.5分
market_value_relevance
1.0分
team_institution_background
0.5分
technical_barrier_competition
0.5分
关键证据
SSD exhibited significant anti-tumor role across different cancer types in vivo and in vitro.
Mechanistically, SSD directly targets PIM1 and blocks the interaction between PIM1 and Myc.
Transcriptome analysis revealed over 200 genes regulated by SSD, impacting various cellular processes.
真实性检查
否
AI评分总结
Saikosaponin-D (SSD), derived from Radix Bupleuri, has been identified as a potent anti-tumor agent targeting the PIM1/c-Myc axis. This study demonstrates SSD's ability to induce cancer cell death by reprogramming oncogenic alternative splicing in gastric and prostate cancers. The findings reveal that SSD significantly inhibits tumor growth in various cancer models, showcasing its potential as a therapeutic candidate. The research emphasizes the innovative mechanism of SSD, which disrupts the PIM1-Myc interaction, leading to decreased Myc phosphorylation and altered splicing factor expression, thereby providing a novel approach to cancer treatment.